Abterra Biosciences specializes in the development of human antibody therapeutics by leveraging advanced technologies such as next-generation sequencing, mass spectrometry, and machine learning. Their proprietary platforms, including Alicanto®, Valens™, and Reptor™, are designed to enhance the discovery and analysis of antibodies. Alicanto® focuses on identifying high-affinity, target-specific antibodies from serum without the need for traditional cell selection methods, making the process more efficient. Valens™ offers a solution for sequencing monoclonal antibodies when the source cells are unavailable, utilizing proteomics to determine full-length amino acid sequences. Reptor™ combines next-generation sequencing with repertoire analysis to provide insights into the immune responses of various species, facilitating a deeper understanding of antibody diversity.

The interdisciplinary approach at Abterra combines expertise in bioinformatics and biology, allowing for innovative solutions in antibody discovery and analysis. Their technologies are built on decades of experience, enabling them to address complex biological challenges effectively. By integrating these advanced methodologies, Abterra aims to push the boundaries of antibody therapeutics, providing valuable services such as custom antibody discovery and protein sequencing. Their commitment to high-quality data generation and rapid turnaround times has garnered positive feedback from partners in the scientific community, highlighting the effectiveness of their platforms in advancing research and therapeutic development.

United States

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

Abterra Biosciences

Company Details